MTOR and metabolic syndrome: The AMPK suppresses the activity of the mammalian target of the Rapamycin Kinase (mTOR) pathway [4,33] thus slowing down disease progression as mTOR is thought to take part in the metabolic syndrome and diabetes progression [33].